Compare PRTH & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTH | PRME |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | 1200 | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.0M | 536.4M |
| IPO Year | N/A | 2022 |
| Metric | PRTH | PRME |
|---|---|---|
| Price | $7.20 | $3.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.33 | $7.56 |
| AVG Volume (30 Days) | 587.3K | ★ 3.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | $9.76 | $7.06 |
| Revenue Next Year | $6.79 | $47.01 |
| P/E Ratio | $10.38 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $4.44 | $2.67 |
| 52 Week High | $8.89 | $6.94 |
| Indicator | PRTH | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 65.67 |
| Support Level | $6.69 | $3.16 |
| Resistance Level | $7.44 | $4.04 |
| Average True Range (ATR) | 0.37 | 0.29 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 80.90 | 71.15 |
Priority Technology Holdings Inc is a fintech company that provides payment and banking-related solutions, including services for collecting, storing, lending, and transferring money for businesses. The company has three reportable segments: i) Merchant Solutions: Provides full-service acquiring and payment-enabled solutions for B2C transactions, ii) Payables: Provides AP automation solutions to corporations, software partners and FIs in addition to improving cash flows by providing instant access to working capital and iii) Treasury Solutions: Provides embedded finance and BaaS solutions to customers to modernize legacy platforms and accelerate software partners' strategies to monetize payments. The majority of the company's revenue is derived from the Merchant Solutions segment.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.